Skip to main content
SpringerLink
Log in
Book cover

Precision Anticoagulation Medicine pp 55–75Cite as

Routine Anticoagulation for the Provoked and Unprovoked VTE

  • Chapter
  • First Online:

  • 1019 Accesses

Abstract

The anticoagulation for venous thromboembolism (VTE) has changed significantly in the last few decades. Multiple agents with novel mechanisms of action have provided new ways of managing VTE, with lower bleeding risks and improved convenience for patients. Clinical studies have significantly enhanced our ability to determine the duration of anticoagulation and the management of thromboembolism in unusual locations. In addition special patient populations like VTE in the extremes of weight, thrombocytopenic patients, pregnancy, and renal failure can now be treated safer than ever before. This chapter will characterize the common therapies used to treat and manage patients with venous thromboembolism, in both provoked and unprovoked setting.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

APS:

Antiphospholipid syndrome

BMI:

Body mass index

CVC:

Central venous catheter

CVST:

Cerebral venous sinus thrombosis

DOACs:

Direct oral anticoagulants

DVT:

Deep vein thrombosis

HIT:

Heparin-induced thrombocytopenia

HITT:

Heparin-induced thrombocytopenia and thrombosis

INR:

International normalized ratio

IVC:

Inferior vena cava

LMWH:

Low-molecular-weight heparin

NSAIDs:

Nonsteroidal anti-inflammatory drugs

OVT:

Ovarian vein thrombosis

PE:

Pulmonary embolism

PTS:

Post-thrombotic syndrome

UFH:

Unfractionated heparin

SVT:

Superficial venous thrombosis

VKA:

Vitamin K antagonist

VTE:

Venous thromboembolism

References

  1. Khilnani NM, et al. Multi-society consensus quality improvement guidelines for the treatment of lower-extremity superficial venous insufficiency with endovenous thermal ablation from the Society of Interventional Radiology, Cardiovascular Interventional Radiological Society of Europe, American College of Phlebology and Canadian Interventional Radiology Association. J Vasc Interv Radiol. 2010;21(1):14–31.

    Article  PubMed  Google Scholar 

  2. Silverstein MD, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93.

    Article  CAS  PubMed  Google Scholar 

  3. Heit JA, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445–53.

    Article  CAS  PubMed  Google Scholar 

  4. Mohr DN, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc. 2000;75(12):1249–56.

    Article  CAS  PubMed  Google Scholar 

  5. Kearon C, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

    Article  PubMed  Google Scholar 

  6. Di Nisio M, van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060–73.

    Article  PubMed  Google Scholar 

  7. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Crowther M. Warfarin: less may be better. Ann Intern Med. 1997;127(4):332; author reply 333.

    Article  Google Scholar 

  9. National Clinical Guideline, C. National Institute for Health and Clinical excellence: guidance. In: Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. London: Royal College of Physicians (UK)National Clinical Guideline Centre; 2012.

    Google Scholar 

  10. Konstantinides SV, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–69, 3069a-3069k.

    Article  CAS  PubMed  Google Scholar 

  11. Canada T. Clinical guidelines. Available from: http://thrombosiscanada.ca/clinicalguides/.

  12. Boutitie F, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011;342:d3036.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Carrier M, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578–89.

    Article  PubMed  Google Scholar 

  14. Castellucci LA, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kearon C, Iorio A, Palareti G. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010;8(10):2313–5.

    Article  CAS  PubMed  Google Scholar 

  16. Iorio A, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710–6.

    Article  PubMed  Google Scholar 

  17. Prandoni P, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.

    Article  PubMed  Google Scholar 

  18. Prandoni P, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  19. Palareti G, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84(5):805–10.

    CAS  PubMed  Google Scholar 

  20. Investigators E, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.

    Article  Google Scholar 

  21. Agnelli G, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.

    Article  CAS  PubMed  Google Scholar 

  22. Schulman S, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18.

    Article  CAS  PubMed  Google Scholar 

  23. Becattini C, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–67.

    Article  CAS  PubMed  Google Scholar 

  24. Brighton TA, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–87.

    Article  CAS  PubMed  Google Scholar 

  25. Canada T. Clinical guidelines superficial thrombophlebitis, superficial vein thrombosis. Available from: http://thrombosiscanada.ca/clinicalguides/.

  26. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21(19):3665–75.

    Article  PubMed  Google Scholar 

  27. Buller HR, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):401S–28S.

    Article  CAS  PubMed  Google Scholar 

  28. Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg. 2003;69(8):654–9.

    PubMed  Google Scholar 

  29. Kaufman JA, et al. Development of a research agenda for inferior vena cava filters: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol. 2009;20(6):697–707.

    Article  PubMed  Google Scholar 

  30. Morales JP, et al. Decision analysis of retrievable inferior vena cava filters in patients without pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2013;1(4):376–84.

    Article  PubMed  Google Scholar 

  31. Jacoby WT, et al. Ovarian vein thrombosis in oncology patients: CT detection and clinical significance. AJR Am J Roentgenol. 1990;155(2):291–4.

    Article  CAS  PubMed  Google Scholar 

  32. Harris K, et al. Ovarian vein thrombosis in the nonpregnant woman: an overlooked diagnosis. Ther Adv Hematol. 2012;3(5):325–8.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Wysokinska EM, Hodge D, McBane RD 2nd. Ovarian vein thrombosis: incidence of recurrent venous thromboembolism and survival. Thromb Haemost. 2006;96(2):126–31.

    Article  CAS  PubMed  Google Scholar 

  34. Piazza G. Cerebral venous thrombosis. Circulation. 2012;125(13):1704–9.

    Article  PubMed  Google Scholar 

  35. Saposnik G, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158–92.

    Article  PubMed  Google Scholar 

  36. Einhaupl K, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229–35.

    Article  CAS  PubMed  Google Scholar 

  37. Cundiff DK. Anticoagulants for cerebral venous thrombosis: harmful to patients? Stroke. 2014;45(1):298–304.

    Article  PubMed  Google Scholar 

  38. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305(4):208–15.

    Article  CAS  PubMed  Google Scholar 

  39. Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol. 1998;16(3):237–47.

    Article  CAS  PubMed  Google Scholar 

  40. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999;50:129–47.

    Article  CAS  PubMed  Google Scholar 

  41. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644–9.

    Article  PubMed  Google Scholar 

  42. Warkentin TE, Eikelboom JW. Who is (still) getting HIT? Chest. 2007;131(6):1620–2.

    Article  PubMed  Google Scholar 

  43. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502–7.

    Article  CAS  PubMed  Google Scholar 

  44. Boshkov LK, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol. 1993;84(2):322–8.

    Article  CAS  PubMed  Google Scholar 

  45. Nand S, et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56(1):12–6.

    Article  CAS  PubMed  Google Scholar 

  46. Warkentin TE, et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest. 2013;144(3):848–58.

    Article  CAS  PubMed  Google Scholar 

  47. Pishko AM. Diagnosis and management of Heparin-Induced Thrombocytopenia (HIT) A POCKET GUIDE FOR THE CLINICIAN DECEMBER 2018. 2018: p. 3.

    Google Scholar 

  48. Martin K, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(6):1308–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Mackay R. Practice guidelines for the management and prophylaxis of thrombosis in cancer patients 2013[cited 2018].

    Google Scholar 

  50. Hughes S, et al. Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J. 2014;7(5):442–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Bayer. Summary of product characteristics—Xarelto (Rivaroxaban) 2019 29 Aug 2018 [cited 2019; Available from: https://www.medicines.org.uk/emc/medicine/21265/SPC.

  52. Squibb-Pfizer B-M. Summary of product characteristics—Eliquis (Apixiban) 19 Mar 2019]; Available from: https://www.medicines.org.uk/emc/medicine/27220/SPC.

  53. Limited BI. Summary of product characteristics—Pradaxa (Dagibatran) 09 Jul 2018 2019]; Available from: https://www.medicines.org.uk/emc/medicine/20760/SPC.

  54. Mantha S, et al. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis. 2017;43(4):514–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Wall C, Moore J, Thachil J. Catheter-related thrombosis: a practical approach. J Intensive Care Soc. 2016;17(2):160–7.

    Article  PubMed  Google Scholar 

  56. Watson HG, et al. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640–8.

    Article  PubMed  Google Scholar 

  57. Bishop L, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007;29(4):261–78.

    Article  CAS  PubMed  Google Scholar 

  58. Baglin T, et al. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34.

    Article  CAS  PubMed  Google Scholar 

  59. Murray J, Precious E, Alikhan R. Catheter-related thrombosis in cancer patients. Br J Haematol. 2013;162(6):748–57.

    Article  PubMed  Google Scholar 

  60. Tripodi A, et al. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Dig Liver Dis. 2016;48(10):1208–13.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saskatoon Cancer Centre, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

    Mark Bosch

Authors
  1. Mark Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Bosch .

Editor information

Editors and Affiliations

  1. Saskatoon Cancer Centre College of Medicine University of Saskatchewan, Saskatoon, SK, Canada

    Hadi Goubran

  2. Faculty of Medicine Cairo University, Giza, Egypt

    Gaafar Ragab

  3. College of Human Medicine Michigan State University, East Lansing, MI, USA

    Suzy Hassouna

Appendix A

Appendix A

figure a

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bosch, M. (2020). Routine Anticoagulation for the Provoked and Unprovoked VTE. In: Goubran, H., Ragab, G., Hassouna, S. (eds) Precision Anticoagulation Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-25782-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25782-8_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25781-1

  • Online ISBN: 978-3-030-25782-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation